Is heparin a placental anticoagulant in high-risk pregnancies?

Blood

Volumn 118, Issue 18, 2011, Pages 4780-4788

  Kingdom, John C P ^a,b   Drewlo, Sascha ^b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

POLYMER;

BARE METAL STENT; DRUG COATING; DRUG ELUTING STENT; HEALING; HUMAN; INFLAMMATION; NEOINTIMA; PRIORITY JOURNAL; REVIEW; STENT THROMBOSIS; THROMBOGENICITY;

EID: 80855133521     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-07-319749     Document Type: Review

References (107)

1. Yinon Y, Siu SC, Warshafsky C, et al. Use of low molecular weight heparin in pregnant women with mechanical heart valves. Am J Cardiol. 2009;104(9):1259-1263.
2. Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133(6 Suppl):844S-886S. (Pubitemid 351892978)
3. Hirsh J, Cade JF, Gallus AS. Fetal effects of Coumadin administered during pregnancy. Blood. 1970;36(5):623-627.
4. Lefkou E, Khamashta M, Hampson G, Hunt BJ. Review: low-molecular-weight heparin-induced osteoporosis and osteoporotic fractures: a myth or an existing entity? Lupus. 2010;19(1):3-12.
5. Buyse FG, Wormgoor BH, Bernard JT, Koudstaal J. Anticoagulant therapy of patients with repeated placental infarction. Obstet Gynecol. 1974;43(6):844-848.
6. Nelson SM, Greer IA. The potential role of heparin in assisted conception. Hum Reprod Update. 2008;14(6):623-645.
7. Urman B, Ata B, Yakin K, et al. Luteal phase empirical low molecular weight heparin administration in patients with failed ICSI embryo transfer cycles: a randomized open-labeled pilot trial. Hum Reprod. 2009;24(7):1640-1647.
8. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ. 1997;314(7076):253-257. (Pubitemid 27047378)
9. Gris JC, Mercier E, Quere I, et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood. 2004;103(10):3695-3699. (Pubitemid 38596284)
10. Ekman-Ordeberg G, Akerud A, Dubicke A, Malmstrom A, Hellgren M. Does low molecular weight heparin shorten term labor? Acta Obstet Gynecol Scand. 2010;89(1):147-150.
11. Casu B, Vlodavsky I, Sanderson RD. Nonanticoagulant heparins and inhibition of cancer. Pathophysiol Haemost Thromb. 2008;36(3-4):195-203.
12. Laskin CA, Spitzer KA, Clark CA, et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol. 2009;36(2):279-287.
13. Clark P, Walker ID, Langhorne P, et al. SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage. Blood. 2010;115(21):4162-4167.
14. Kaandorp SP, Goddijn M, van der Post JA, et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med. 2010;362(17):1586-1596.
15. Branch DW, Gibson M, Silver RM. Clinical practice. Recurrent miscarriage. N Engl J Med. 2010;363(18):1740-1747.
16. Ball E, Robson SC, Ayis S, Lyall F, Bulmer JN. Early embryonic demise: no evidence of abnormal spiral artery transformation or trophoblast invasion. J Pathol. 2006;208(4):528-534. (Pubitemid 43329339)
17. Dodd JM, McLeod A, Windrim RC, Kingdom J. Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction. Cochrane Database Syst Rev. 2010;(6):CD006780.
18. Rey E, Garneau P, David M, et al. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost. 2009;7(1):58-64.
19. Gris JC, Chauleur C, Faillie JL, et al. Enoxaparin for the secondary prevention of placental vascular complications in women with abruptio placentae. The pilot randomised controlled NOH-AP trial. Thromb Haemost. 2010;104(4):771-779.
20. Kupferminc MJ, Rimon E, Many A, et al. Low molecular weight heparin treatment during subsequent pregnancies of women with inherited thrombophilia and previous severe pregnancy complications. J Matern Fetal Neonat Med. 2011;24(8):1042-1045.
21. Kupferminc M, Rimon E, Many A, et al. Low molecular weight heparin versus no treatment in women with previous severe pregnancy complications and placental findings without thrombophilia. Blood Coagul Fibrinolysis. 2011;22(2):123-126.
22. Jauniaux E, Gulbis B, Burton GJ. The human first trimester gestational sac limits rather than facilitates oxygen transfer to the foetus-a review. Placenta. 2003;24(Suppl A):S86-S93. (Pubitemid 37184740)
23. Burton GJ, Watson AL, Hempstock J, Skepper JN, Jauniaux E. Uterine glands provide histiotrophic nutrition for the human fetus during the first trimester of pregnancy. J Clin Endocrinol Metab. 2002;87(6):2954-2959. (Pubitemid 34655369)
24. Burton GJ, Jauniaux E, Watson AL. Maternal arterial connections to the placental intervillous space during the first trimester of human pregnancy: the Boyd collection revisited. Am J Obstet Gynecol. 1999;181(3):718-724. (Pubitemid 29453538)
25. Lockwood CJ, Huang SJ, Krikun G, et al. Decidual hemostasis, inflammation, and angiogenesis in pre-eclampsia. Semin Thromb Hemost. 2011;37(2):158-164.
26. Carmeliet P, Mackman N, Moons L, et al. Role of tissue factor in embryonic blood vessel development. Nature. 1996;383(6595):73-75. (Pubitemid 26296462)
27. Isermann B, Sood R, Pawlinski R, et al. The thrombomodulin-protein C system is essential for the maintenance of pregnancy. Nat Med. 2003;9(3):331-337. (Pubitemid 36362789)
28. Robson SC, Simpson H, Ball E, Lyall F, Bulmer JN. Punch biopsy of the human placental bed. Am J Obstet Gynecol. 2002;187(5):1349-1355. (Pubitemid 35397485)
29. Zhou Y, Fisher SJ, Janatpour M, et al. Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion? J Clin Invest. 1997;99(9):2139-2151. (Pubitemid 27203770)
30. Hering L, Herse F, Verlohren S, et al. Trophoblasts reduce the vascular smooth muscle cell proatherogenic response. Hypertension. 2008;51(2):554-559. (Pubitemid 351156447)
31. Burton GJ, Woods AW, Jauniaux E, Kingdom JC. Rheological and physiological consequences of conversion of the maternal spiral arteries for uteroplacental blood flow during human pregnancy. Placenta. 2009;30(6):473-482.
32. Bagot CN, Arya R. Virchow and his triad: a question of attribution. Br J Haematol. 2008;143(2):180-190.
33. O'Riordan MN, Higgins JR. Haemostasis in normal and abnormal pregnancy. Best Pract Res Clin Obstet Gynaecol. 2003;17(3):385-396. (Pubitemid 36722166)
34. Uchikova EH, Ledjev II. Changes in haemostasis during normal pregnancy. Eur J Obstet Gynecol Reprod Biol. 2005;119(2):185-188. (Pubitemid 40460379)
35. Thornton P, Douglas J. Coagulation in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2010;24(3):339-352.
36. Sarig G, Brenner B. Coagulation, inflammation, and pregnancy complications. Lancet. 2004;363(9403):96-97. (Pubitemid 38068323)
37. van Buul EJ, Steegers EA, Jongsma HW, et al. Haematological and biochemical profile of uncomplicated pregnancy in nulliparous women; a longitudinal study. Neth J Med. 1995;46(2):73-85.
38. Robson SC, Hunter S, Boys RJ, Dunlop W. Serial study of factors influencing changes in cardiac output during human pregnancy. Am J Physiol. 1989;256(4 Pt 2):H1060-H1065.
39. Ittel A, Bretelle F, Gris JC, et al. Increased risk of gestational vascular complications in women with low free tissue factor pathway inhibitor plasma levels out of pregnancy. Thromb Haemost. 2011;105(1):66-71.
40. Simmons DG, Natale DR, Begay V, et al. Early patterning of the chorion leads to the trilaminar trophoblast cell structure in the placental labyrinth. Development. 2008;135(12):2083-2091. (Pubitemid 352015143)
41. Mayhew TM, Simpson RA. Quantitative evidence for the spatial dispersal of trophoblast nuclei in human placental villi during gestation. Placenta. 1994;15(8):837-844.
42. Ellery PM, Cindrova-Davies T, Jauniaux E, Ferguson-Smith AC, Burton GJ. Evidence for transcriptional activity in the syncytiotrophoblast of the human placenta. Placenta. 2009;30(4):329-334.
43. Huppertz B, Kadyrov M, Kingdom JC. Apoptosis and its role in the trophoblast. Am J Obstet Gynecol. 2006;195(1):29-39. (Pubitemid 43927489)
44. Baczyk D, Drewlo S, Proctor L, et al. Glial cell missing-1 transcription factor is required for the differentiation of the human trophoblast. Cell Death Differ. 2009;16(5):719-727.
45. Parast MM, Yu H, Ciric A, et al. PPARgamma regulates trophoblast proliferation and promotes labyrinthine trilineage differentiation. PLoS One. 2009;4(11):e8055.
46. Mi S, Lee X, Li X, et al. Syncytin is a captive retroviral envelope protein involved in human placental morphogenesis. Nature. 2000;403(6771):785- 789. (Pubitemid 30111841)
47. Sood R, Kalloway S, Mast AE, Hillard CJ, Weiler H. Fetomaternal cross talk in the placental vascular bed: control of coagulation by trophoblast cells. Blood. 2006;107(8):3173-3180.
48. Kadhom N, Wolfrom C, Gautier M, Allain JP, Frommel D. Factor VIII procoagulant antigen in human tissues. Thromb Haemost. 1988;59(2):289-294.
49. Mast AE, Acharya N, Malecha MJ, Hall CL, Dietzen DJ. Characterization of the association of tissue factor pathway inhibitor with human placenta. Arterioscler Thromb Vasc Biol. 2002;22(12):2099-2104. (Pubitemid 36025221)
50. Sprecher CA, Kisiel W, Mathewes S, Foster DC. Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor. Proc Natl Acad Sci U S A. 1994;91(8):3353-3357. (Pubitemid 24130235)
51. Freyssinet JM, Brami B, Gauchy J, Cazenave JP. Coextraction of thrombomodulin and tissue factor from human placenta: effects of concanavalin A and phospholipid environment on activity. Thromb Haemost. 1986;55(1):112-118. (Pubitemid 16117245)
52. Salem HH, Maruyama I, Ishii H, Majerus PW. Isolation and characterization of thrombomodulin from human placenta. J Biol Chem. 1984;259(19):12246-12251. (Pubitemid 14019764)
53. Krikun G, Lockwood CJ, Wu XX, et al. The expression of the placental anticoagulant protein, annexin V, by villous trophoblasts: immunolocalization and in vitro regulation. Placenta. 1994;15(6):601-612. (Pubitemid 24295067)
54. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. 2010;376(9741):631-644.
55. North RA, McCowan LM, Dekker GA, et al. Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort. BMJ. 2011;342:d1875.
56. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005;308(5728):1592-1594. (Pubitemid 40807500)
57. Moldenhauer JS, Stanek J, Warshak C, Khoury J, Sibai B. The frequency and severity of placental findings in women with preeclampsia are gestational age dependent. Am J Obstet Gynecol. 2003;189(4):1173-1177. (Pubitemid 37373917)
58. Toal M, Keating S, Machin G, et al. Determinants of adverse perinatal outcome in high-risk women with abnormal uterine artery Doppler images. Am J Obstet Gynecol. 2008;198(3):330;e331-337.
59. Franco C, Walker M, Robertson J, et al. Placental infarction and thrombophilia. Obstet Gynecol. 2011;117(4):929-934.
60. Koopmans CM, Bijlenga D, Groen H, et al. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet. 2009;374(9694):979-988.
61. von Dadelszen P, Payne B, Li J, et al. Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the full-PIERS model. Lancet. 2011;377(9761):219-227.
62. Yu CK, Smith GC, Papageorghiou AT, Cacho AM, Nicolaides KH. An integrated model for the prediction of preeclampsia using maternal factors and uterine artery Doppler velocimetry in unselected low-risk women. Am J Obstet Gynecol. 2005;193(2):429-436. (Pubitemid 41159538)
63. Toal M, Chaddha V, Windrim R, Kingdom J. Ultrasound detection of placental insufficiency in women with elevated second trimester serum alpha-fetoprotein or human chorionic gonadotropin. J Obstet Gynaecol Can. 2008;30(3):198-206.
64. Sep S, Schreurs M, Bekkers S, et al. Early-pregnancy changes in cardiac diastolic function in women with recurrent pre-eclampsia and in previously pre-eclamptic women without recurrent disease. BJOG. 2011;118(9):1112-1119.
65. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350(7):672-683. (Pubitemid 38364626)
66. Powe CE, Levine RJ, Karumanchi SA. Pre-eclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation. 2011;123(24):2856-2869.
67. Murphy SR, LaMarca BB, Cockrell K, Granger JP. Role of endothelin in mediating soluble fms-like tyrosine kinase 1-induced hypertension in pregnant rats. Hypertension. 2010;55(2):394-398.
68. Bergmann A, Ahmad S, Cudmore M, et al. Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model. J Cell Mol Med. 2010;14(6B):1857-1867.
69. Smith GC, Crossley JA, Aitken DA, et al. Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth, and stillbirth. Obstet Gynecol. 2007;109(6):1316-1324. (Pubitemid 46869870)
70. Sela S, Natanson-Yaron S, Zcharia E, et al. Local retention versus systemic release of soluble VEGF receptor-1 are mediated by heparin-binding and regulated by heparanase. Circ Res. 2011;108(9):1063-1070.
71. Ambati BK, Nozaki M, Singh N, et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature. 2006;443(7114):993-997. (Pubitemid 44646176)
72. Carroll TY, Mulla MJ, Han CS, et al. Modulation of trophoblast angiogenic factor secretion by antiphospholipid antibodies is not reversed by heparin [published online ahead of print May 7, 2011]. Am J Reprod Immunol. Diu:10.1111/j:1600-0897.2011.01007.
73. Drewlo S, Levytska K, Sobal M, et al. Heparin promotes soluble VEGF receptor expression in human placental villi to impair endothelial VEGF signaling [published online ahead of print October 10, 2011]. J Thromb Hemost. doi 10.1111/j.1538-7836.2011.04526.x.
74. Reister F, Frank HG, Kingdom JC, et al. Macrophage-induced apoptosis limits endovascular trophoblast invasion in the uterine wall of pre-eclamptic women. Lab Invest. 2001;81(8):1143-1152. (Pubitemid 32772074)
75. Ferrazzi E, Bulfamante G, Mezzopane R, et al. Uterine Doppler velocimetry and placental hypoxic-ischemic lesion in pregnancies with fetal intrauterine growth restriction. Placenta. 1999;20(5-6):389-394. (Pubitemid 29301611)
76. Soleymanlou N, Jurisica I, Nevo O, et al. Molecular evidence of placental hypoxia in preeclampsia. J Clin Endocrinol Metab. 2005;90(7):4299-4308. (Pubitemid 41058212)
77. Hung TH, Skepper JN, Charnock-Jones DS, Burton GJ. Hypoxia-reoxygenation: a potent inducer of apoptotic changes in the human placenta and possible etiological factor in pre-eclampsia. Circ Res. 2002;90(12):1274-1281. (Pubitemid 34787409)
78. McCarthy FP, Drewlo S, Kingdom J, et al. Peroxisome proliferator- activated receptor-{gamma} as a potential therapeutic target in the treatment of preeclampsia. Hypertension. 2011;58(2):280-286.
79. Chen CP, Chen CY, Yang YC, Su TH, Chen H. Decreased placental GCM1 (glial cells missing) gene expression in pre-eclampsia. Placenta. 2004;25(5):413-421. (Pubitemid 38519115)
80. Vargas A, Toufaily C, Lebellego F, et al. Reduced expression of both Syncytin 1 and Syncytin 2 correlates with severity of preeclampsia [published online ahead of print April 14, 2011]. Reprod Sci. doi:10.1177/1933719111404608.
81. Wich C, Kausler S, Dotsch J, Rascher W, Knerr I. Syncytin-1 and glial cells missing a: hypoxia-induced deregulated gene expression along with disordered cell fusion in primary term human trophoblasts. Gynecol Obstet Invest. 2009;68(1):9-18.
82. Chiang MH, Liang FY, Chen CP, et al. Mechanism of hypoxia-induced GCM1 degradation: implications for the pathogenesis of preeclampsia. J Biol Chem. 2009;284(26):17411-17419.
83. Fitzgerald B, Levytska K, Kingdom J, et al. Villous trophoblast abnormalities in extremely preterm deliveries with elevated second trimester maternal serum hCG or inhibin-A. Placenta. 2011;32(4):339-345.
84. Huppertz B, Kingdom J, Caniggia I, et al. Hypoxia favours necrotic versus apoptotic shedding of placental syncytiotrophoblast into the maternal circulation. Placenta. 2003;24(2-3):181-190. (Pubitemid 37184714)
85. Tache V, Lacoursiere DY, Saleemuddin A, Parast MM. Placental expression of vascular endothelial growth factor receptor-1/soluble vascular endothelial growth factor receptor-1 correlates with severity of clinical preeclampsia and villous hypermaturity. Hum Pathol. 2011;42(9):1283-1288.
86. Teng YC, Lin QD, Lin JH, Ding CW, Zuo Y. Coagulation and fibrinolysis related cytokine imbalance in preeclampsia: the role of placental trophoblasts. J Perinat Med. 2009;37(4):343-348.
87. Aharon A, Brenner B. Microparticles and pregnancy complications. Thromb Res. 2011;127(suppl 3):S67-S71.
88. Knight M, Redman CW, Linton EA, Sargent IL. Shedding of syncytiotrophoblast microvilli into the maternal circulation in pre-eclamptic pregnancies. Br J Obstet Gynaecol. 1998;105(6):632-640. (Pubitemid 28293481)
89. Lazo-Langner A, Goss GD, Spaans JN, Rodger MA. The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J Thromb Haemost. 2007;5(4):729-737. (Pubitemid 46563571)
90. Marchetti M, Vignoli A, Russo L, et al. Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin. Thromb Res. 2008;121(5):637-645. (Pubitemid 351305285)
91. Khorana AA, Sahni A, Altland OD, Francis CW. Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight. Arterioscler Thromb Vasc Biol. 2003;23(11):2110-2115. (Pubitemid 37433208)
92. Tanaka S, Kunath T, Hadjantonakis AK, Nagy A, Rossant J. Promotion of trophoblast stem cell proliferation by FGF4. Science. 1998;282(5396):2072-2075. (Pubitemid 29001261)
93. Hughes M, Dobric N, Scott IC, et al. The Hand1, Stra13 and Gcm1 transcription factors override FGF signaling to promote terminal differentiation of trophoblast stem cells. Dev Biol. 2004;271(1):26-37. (Pubitemid 38757772)
94. Baczyk D, Dunk C, Huppertz B, et al. Bi-potential behaviour of cytotrophoblasts in first trimester chorionic villi. Placenta. 2006;27(4-5):367-374.
95. Hills FA, Abrahams VM, Gonzalez-Timon B, et al. Heparin prevents programmed cell death in human trophoblast. Mol Hum Reprod. 2006;12(4):237-243. (Pubitemid 43779075)
96. Bose P, Black S, Kadyrov M, et al. Adverse effects of lupus anticoagulant positive blood sera on placental viability can be prevented by heparin in vitro. Am J Obstet Gynecol. 2004;191(6):2125-2131. (Pubitemid 39601524)
97. Sobel ML, Kingdom J, Drewlo S. angiogenic response of placental villi to heparin. Obst Gynecol. 2011;117(6):1375-1383.
98. George EM, Cockrell K, Aranay M, et al. Induction of heme oxygenase 1 attenuates placental ischemia-induced hypertension. Hypertension. 2011;57(5):941-948.
99. Lynch AM, Murphy JR, Gibbs RS, et al. The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia. BJOG. 2010;117(4):456-462.
100. Salmon JE, Heuser C, Triebwasser M, et al. Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. PLoS Med. 2011;8(3):e1001013.
101. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med. 2004;10(11):1222-1226. (Pubitemid 39540439)
102. Christopherson KW II, Campbell JJ, Travers JB, Hromas RA. Low-molecular-weight heparins inhibit CCL21-induced T cell adhesion and migration. J Pharmacol Exp Ther. 2002;302(1):290-295. (Pubitemid 34680450)
103. Kuc S, Wortelboer EJ, van Rijn BB, et al. Evaluation of 7 serum biomarkers and uterine artery Doppler ultrasound for first-trimester prediction of preeclampsia: a systematic review. Obstet Gynecol Surv. 2011;66(4):225-239.
104. Dugoff L. First- and second-trimester maternal serum markers for aneuploidy and adverse obstetric outcomes. Obstet Gynecol. 2010;115(5):1052- 1061.
105. Proctor L, Toal M, Drewlo S, et al. Role of placental ultrasound to predict adverse pregnancy outcomes in women with low PAPP-A at 11-13 weeks. Placenta. 2007;28(8-9):A41-A41.
106. Toal M, Chan C, Fallah S, et al. Usefulness of a placental profile in high-risk pregnancies. Am J Obstet Gynecol. 2007;196(4):363;e361-367.
107. Kingdom JC, Walker M, Proctor LK, et al. Unfractionated heparin for second trimester placental insufficiency: a pilot randomized trial. J Thromb Haemost. 2011;9(8):1783-1492.